Asset Details
Do you wish to reserve the book?
Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier
Do you wish to request the book?
Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier
2017
Overview
To achieve synergistic therapeutic efficacy and prevent cancer relapse, chemotherapy and immunotherapy have been combined as a new modality for tumor treatment. In this work, we designed a redox-responsive immunostimulatory polymeric prodrug carrier, PSSNIO, for programmable co-delivery of an immune checkpoint inhibitor NLG919 （NLG） and a chemotherapeutic doxorubicin （DOX）, NLG-containing PSSNIO prodrug polymers were self-assembled into nano-sized micelles that served as a carrier to load DOX （DOX/ PSSNIO micelles）. DOX/PSSNIO micelles displayed spherical morphology with a size of -170 nm. DOX was effectively loaded into PSSNIO micelles with a loading efficiency of 84.0%. In vitro DOX release studies showed that rapid drug release could be achieved in the highly redox environment after intracellular uptake by tumor cells. In 4T1.2 tumor-bearing mice, DOX/PSSNIO micelles exhibited greater accumulation of DOX and NLG in the tumor tissues compared with other organs. The PSSNIO carrier dose-dependently enhanced T-cell immune responses in the lymphocyte-Panc02 co-culture experiments, and significantly inhibited tumor growth in vivo. DOX/PSSNIO micelles showed potent cytotoxicity in vitro against 4T1.2 mouse breast cancer cells and PC-3 human prostate cancer cells comparable to that of DOX. In 4T1.2 tumor-bearing mice, DOX/PSSNIO mixed micelles （5 mg DOX/kg, iv） was more effective than DOXlL （a clinical formulation of liposomal DOX） or free DOX in inhibiting the tumor growth and prolonging the survival of the treated mice. In addition, a more immunoactive tumor microenvironment was observed in the mice treated with PSSNIO or DOX/ PSSNIO micelles compared with the other treatment groups. In conclusion, systemic delivery of DOX via PSSNIO nanocarrier results in synergistic anti-tumor activity.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Antineoplastic Agents - chemistry
/ Antineoplastic Agents - pharmacology
/ Biomedical and Life Sciences
/ Cell Proliferation - drug effects
/ Dose-Response Relationship, Drug
/ Drug Screening Assays, Antitumor
/ Female
/ Humans
/ Mice
/ Micelles
/ Original
/ Structure-Activity Relationship
/ T-Lymphocytes - drug effects
/ Vaccine
/ 免疫刺激活性
/ 化疗药物
/ 可编程
/ 抑制剂
/ 检查点
/ 氧化还原反应
/ 纳米载体
/ 阿霉素
